HemCon Medical Technologies, a provider of hemostatic bandages, has received a new FDA indication for its HemCon Bandage for use in cardiac catheterization laboratories and other endovascular settings.

The Portland, Ore.-based company said its HemCon Bandage, in addition to its use for external, temporary control of high-pressure, high-flow arterial bleeding wounds in emergency situations, is now indicated for the control of bleeding from the skin at percutaneous needle access, vascular access and percutaneous catheter access sites in cath labs.

HemCon products have been exclusively distributed by the Dubin, Ohio-based Cardinal Health in acute-care settings since 2007.